Real-World Outcomes of Everolimus and Exemestane for the Treatment of Metastatic Hormone Receptor-Positive Breast Cancer in Patients Previously Treated With CDK4/6 Inhibitors.
Sign Up to like & getrecommendations! Published in 2021 at "Clinical breast cancer"
DOI: 10.1016/j.clbc.2021.10.002
Abstract: PURPOSE Everolimus with exemestane (EVE+EXE) was FDA-approved to treat metastatic hormone receptor-positive breast cancer (mHRBC) based on BOLERO-2. However, none of those patients received prior CDK4/6 inhibitors. The purpose of this study is to evaluate… read more here.
Keywords: prior cdk4; eve exe; cdk4; breast cancer ... See more keywords